In vivo, daily intraperitoneal administration of atorvastatin (5–10 mg/kg) via SLNs led to a notable tumor volume reduction and increased caspase-3–mediated apoptosis, with Lf-SLNs producing the strongest effect. Here, CASP3 is linked to neoplasm.